Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent-Reference-Cited by-同舟云学术

Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent

Published:2021-12-06 Issue:12 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Zhu Jianwei¹,Yuan Yun²,Wan Xiaoyu²,Yin Dan²,Li Rui³,Chen Wenwen²,Suo Chen⁴,Song Huan²⁵

Affiliation:

1. Department of Orthopaedics; West China Hospital, Sichuan University; Chengdu China

2. West China Biomedical Big Data Center; West China Hospital, Sichuan University; Chengdu China

3. Thoracic Oncology; Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University; Chengdu China

4. Key Laboratory of Public Health Safety; Fudan University, Ministry of Education; Shanghai China

5. Center of Public Health Sciences, Faculty of Medicine; University of Iceland; Reykjavík Iceland

Publisher

Wiley

Subject

Pharmacology (medical)

Reference70 articles.

1. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer(START): a randomised, double-blind, phase 3 trial;Butts;Lancet Oncolology,2014

2. Postoperative immunostimulation after complete resection improves survival of patients with stage I non-small cell lung carcinoma;Fujisawa;Cancer,1996

3. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma;Giovanni;Cancer,1996

4. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer;Katakami;Lung Cancer,2017

5. Long-term evaluation of intrapleural Bacillus Calmette-Guérin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer;Macchiarini;American Journal of Clinical Oncology,1991

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research on sustainable green building space design model integrating IoT technology;PLOS ONE;2024-04-29

2. Therapeutic vaccines for advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-03-12

3. FUT3 facilitates glucose metabolism of lung adenocarcinoma via activation of NF-κB pathway;BMC Pulmonary Medicine;2023-11-09

4. Drug resistance mechanism and reversal strategy in lung cancer immunotherapy;Frontiers in Pharmacology;2023-09-19

5. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials;Frontiers in Immunology;2023-08-08